Nanobiotix (NANO) Stock Overview
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
NANO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Nanobiotix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €31.30 |
| 52 Week High | €47.66 |
| 52 Week Low | €7.92 |
| Beta | 0.57 |
| 1 Month Change | -9.33% |
| 3 Month Change | 2.29% |
| 1 Year Change | 273.95% |
| 3 Year Change | 252.87% |
| 5 Year Change | 205.96% |
| Change since IPO | 404.84% |
Recent News & Updates
Narrative Update • Aug 07
NANO: CONVERGE Lung Cancer Efficacy Data Will Drive Future Repricing
Analysts have lifted the Nanobiotix fair value estimate from €47.80 to €52.20 after a sharp increase in the Street price target to €60, citing updated efficacy results from Part 1 of the Phase 2 CONVERGE study for JNJ-1900 in stage 3 inoperable non small cell lung cancer as key support. What’s in the News for Nanobiotix Nanobiotix completed a follow on equity offering of €85 million, including American Depositary Shares, ordinary shares and pre funded warrants, with per security prices in the €33.57 to €33.60 range and discounts of about €2 per security.
Narrative Update • Jul 24
NANO: CONVERGE Data Will Drive Bullish Repricing Despite Execution Risks
The analyst price target for Nanobiotix has moved from €21.50 to €40.00, with analysts citing updated efficacy data from the Phase 2 CONVERGE study and recent target increases to around €60.00 as key drivers of their revised outlook. Analyst Commentary Recent research updates around Nanobiotix focus heavily on how the Phase 2 CONVERGE efficacy data may affect long term execution, growth prospects and valuation risk.Narrative Update • Jul 10
NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects
Nanobiotix sees its analyst fair value estimate move from €29.24 to €47.80, with analysts pointing to recent upward revisions in price targets following updated CONVERGE study data as key support for the change. Analyst Commentary Recent research updates on Nanobiotix focus on the latest efficacy readouts from the Phase 2 CONVERGE study and how these data points feed into valuation frameworks and execution risk for the company.
Narrative Update • Jun 26
NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects
Analysts have raised their fair value estimate for Nanobiotix from €45.00 to €60.00, citing recent price target increases and supportive efficacy data from updated Phase 2 CONVERGE study results. Analyst Commentary Recent Street research on Nanobiotix reflects a cluster of higher price targets following updated efficacy data from the Phase 2 CONVERGE study.Recent updates
Narrative Update • Aug 07
NANO: CONVERGE Lung Cancer Efficacy Data Will Drive Future Repricing
Analysts have lifted the Nanobiotix fair value estimate from €47.80 to €52.20 after a sharp increase in the Street price target to €60, citing updated efficacy results from Part 1 of the Phase 2 CONVERGE study for JNJ-1900 in stage 3 inoperable non small cell lung cancer as key support. What’s in the News for Nanobiotix Nanobiotix completed a follow on equity offering of €85 million, including American Depositary Shares, ordinary shares and pre funded warrants, with per security prices in the €33.57 to €33.60 range and discounts of about €2 per security.Narrative Update • Jul 24
NANO: CONVERGE Data Will Drive Bullish Repricing Despite Execution Risks
The analyst price target for Nanobiotix has moved from €21.50 to €40.00, with analysts citing updated efficacy data from the Phase 2 CONVERGE study and recent target increases to around €60.00 as key drivers of their revised outlook. Analyst Commentary Recent research updates around Nanobiotix focus heavily on how the Phase 2 CONVERGE efficacy data may affect long term execution, growth prospects and valuation risk.Narrative Update • Jul 10
NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects
Nanobiotix sees its analyst fair value estimate move from €29.24 to €47.80, with analysts pointing to recent upward revisions in price targets following updated CONVERGE study data as key support for the change. Analyst Commentary Recent research updates on Nanobiotix focus on the latest efficacy readouts from the Phase 2 CONVERGE study and how these data points feed into valuation frameworks and execution risk for the company.Narrative Update • Jun 26
NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects
Analysts have raised their fair value estimate for Nanobiotix from €45.00 to €60.00, citing recent price target increases and supportive efficacy data from updated Phase 2 CONVERGE study results. Analyst Commentary Recent Street research on Nanobiotix reflects a cluster of higher price targets following updated efficacy data from the Phase 2 CONVERGE study.New Narrative • Apr 30
Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential
Catalysts About Nanobiotix Nanobiotix develops nanoparticle based drug candidates intended to improve the effectiveness of existing cancer treatments such as radiotherapy and complex systemic therapies. What are the underlying business or industry changes driving this perspective?New Narrative • Apr 16
Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment
Catalysts About Nanobiotix Nanobiotix develops nanotechnology based therapies designed to work alongside existing cancer treatments such as radiotherapy. What are the underlying business or industry changes driving this perspective?New Narrative • Apr 01
Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech
Catalysts About Nanobiotix Nanobiotix is a biotechnology company focused on nanoscale therapies designed to work with existing treatments such as radiotherapy and complex biologic drugs. What are the underlying business or industry changes driving this perspective?Analysis Article • Jan 31
New Forecasts: Here's What Analysts Think The Future Holds For Nanobiotix S.A. (EPA:NANO)
Nanobiotix S.A. ( EPA:NANO ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • Mar 14
Risks Still Elevated At These Prices As Nanobiotix S.A. (EPA:NANO) Shares Dive 27%
Nanobiotix S.A. ( EPA:NANO ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Nov 28
Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%
To the annoyance of some shareholders, Nanobiotix S.A. ( EPA:NANO ) shares are down a considerable 26% in the last...Analysis Article • Jun 29
Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Nanobiotix S.A. ( EPA:NANO ) share price has fared very poorly over the last month, falling by a substantial 27...Analysis Article • May 14
Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%
Nanobiotix S.A. ( EPA:NANO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...Analysis Article • Apr 26
We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • May 11
Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Dec 06
Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Jun 04
Is Nanobiotix (EPA:NANO) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Shareholder Returns
| NANO | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -6.6% | -0.007% | -2.3% |
| 1Y | 274.0% | 25.6% | -1.1% |
Return vs Industry: NANO exceeded the French Biotechs industry which returned 25.6% over the past year.
Return vs Market: NANO exceeded the French Market which returned -1.1% over the past year.
Price Volatility
| NANO volatility | |
|---|---|
| NANO Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: NANO's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: NANO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 100 | Laurent Levy | www.nanobiotix.com |
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. Fundamentals Summary
| NANO fundamental statistics | |
|---|---|
| Market cap | €1.59b |
| Earnings (TTM) | -€23.96m |
| Revenue (TTM) | €32.59m |
48.8x
P/S Ratio-66.4x
P/E RatioIs NANO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANO income statement (TTM) | |
|---|---|
| Revenue | €32.59m |
| Cost of Revenue | €0 |
| Gross Profit | €32.59m |
| Other Expenses | €56.55m |
| Earnings | -€23.96m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -73.52% |
| Debt/Equity Ratio | -109.2% |
How did NANO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/11 23:33 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanobiotix S.A. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Philippa Gardner | Edison Investment Research |
| Jonathan Miller | Evercore ISI |
| Emmanuel Parot | Gilbert Dupont |